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Abstract 
 
HIV incidence rates have remained relatively stable throughout the past five years; 
however, among men who have sex with men (MSM), particularly young MSM, 
incidence has increased. According to national surveillance data, MSM accounted for 
61% of HIV cases diagnosed in 2010. A low viral load reduces the risk of HIV 
transmission and slows the progression of HIV to AIDS. Treatment as prevention (TasP) 
has been identified as a major part of the solution to ending the HIV epidemic. This 
research focuses specifically on reasons for not taking an HIV-test among MSM. For 
TasP to be effective, widespread testing in order to identify HIV-positive people is 
needed. For the purpose of the present study, a survey was distributed at gay pride events 
in Rochester and Buffalo, NY during June and July 2012. Barriers to HIV testing and 
HIV risk were evaluated using a four-point Likert scale adapted from an instrument 
developed by Mikolajczak (2006). It was hypothesized that months since last HIV test 
would be positively correlated with barriers to testing. Months since last HIV test was 
positively skewed, ranging from 0 to 348 months. Therefore, Spearman rank-order 
correlations were used. Three items measuring barriers to testing were significantly 
correlated with months since last HIV test. These were perceived peer support, 
knowledge of HIV testing sites, and partnered relationship status. Interestingly, previous 
research suggested that fear of a positive result and low perceived risk were barriers to 
testing. These findings were not replicated in this sample. Nearly 40% of subjects had not 
been tested within the last year. TasP would not effectively prevent transmission among 
an untested group such as this. For TasP to be effective, interventions must be designed 
to encourage more frequent HIV testing and safer sex among those who have not been 
recently tested.  
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Introduction 
For decades our world has fought one of the most devastating threats to human 
health. The World Health Organization (WHO) estimated that there are approximately 34 
million people living with HIV/AIDS.1 Within the United States, there are roughly 1.2 
million people living with HIV/AIDS.2 Through the course of the AIDS epidemic, men 
who have sex with men (MSM) have been one of the groups at highest risk for HIV-
infection in developed nations.3 Overall, HIV incidence rates have remained relatively 
stable throughout the past five years; however, among MSM, particularly young MSM, 
incidence has increased.4 The Centers for Disease Control and Prevention (CDC) 
estimated that MSM account for just 2% of the male population aged 13 and older.3 
According to national surveillance data, MSM accounted for 61% of HIV cases 
diagnosed in 2010.3 
These current prevalence and incidence rates suggest a serious threat for the 
future social and economic development of the United States. In 2012, the federal budget 
request included a total of $21.5 billion for domestic HIV/AIDS funding.5 The 2013 
federal budget request includes a $22.25 billion for domestic HIV/AIDS funding.6 Gay 
and bisexual men living with HIV/AIDS are forced to undergo serious financial, social, 
emotional, and medical changes.7 Stigma and discrimination are still very much 
associated with this condition, as well as high costs of anti-retroviral therapy (ART). 7 
HIV/AIDS damages the immune system, causing a higher risk for opportunistic 
infections, like other sexually transmitted infections (STI).7 In many cases, there is an 
associated need for counseling and support groups for the friends and family affected by 
this condition.7  
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Still, the number of people living with HIV in the United States is growing by 
approximately 54,000 every year. ART is significantly extending lives, but funding will 
have to increase substantially to keep up with the needs of HIV-positive people.8 
Treatment as prevention (TasP) has been identified as a major part of the solution to 
ending the HIV epidemic, which is why this research is so essential.9 In order for TasP to 
be effective, there are a number of issues to address.  
It is important to understand how TasP is used to prevent the transmission of HIV. 
ART decreases the amount of the virus in the person’s body, known as the viral load. A 
low viral load reduces the risk of HIV transmission and slows the progression of HIV to 
AIDS. A study reported by the HIV Prevention Trials Network (HPTN), reported that 
HIV-positive individuals who take ART could reduce their transmissibility of HIV by 
96%. This clinical trial, known as HPTN 052, demonstrated that treating HIV infected 
individuals could have a major impact when reducing HIV transmission.10 Based on this 
finding, TasP has become a major focus of the primary prevention, potentially reducing 
the behavioral risk reduction approaches used to date (e.g. safer sex).  
Research has indicated that ART is safe and highly effective in suppressing the 
replication of HIV. Nevertheless, HIV does replicate, and with the accumulation of 
resistant mutations, HIV becomes resilient to the effects of ART.11 Research has 
identified common and predictable adverse reactions associated with ART. ART must be 
taken properly, as adherence to ART is one of the most important predictors to treatment 
effectiveness. Adverse reactions to medications must be managed individually to assure 
proper adherence to ART. Patients have described any number of adverse effects after 
starting new medications, all in which will decide the success of TasP.12 
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To identify HIV infections, the CDC recommends sexually active MSM undergo 
routine HIV testing at least once every 12 months. MSM must perform routine testing 
and prevent the unknowing transmission of HIV.13 However, if MSM test too soon after 
exposure, there is a chance that HIV is not detected. Testing during a window period may 
give a false negative result and this could be anywhere from 9 days to 3-6 months.14 
Since 2010, the WHO guidelines recommend starting treatment when CD4 count 
reaches 350 cells/mm3.15 The AIDS Drug Assistance Programs (ADAPs) provides ART 
to underinsured and uninsured patients living with HIV/AIDS in the United States. Each 
state operates its own ADAP under Title II of the Ryan White Comprehensive AIDS 
Resources Emergency (CARE) Act. The Patient Protection and Affordable Health Care 
Act (PPACA) will increase access to treatment and care for HIV-positive people. 
However, most of these changes do not come into force until 2014 and there are still 
many inequalities and barriers to overcome.16 17 The Medicare Part D prescription drug 
benefit plan will provide patients with lower cost ART. Beginning in 2014, under the Pre-
existing Condition Insurance Plan, insurers will not be allowed to deny coverage to 
anyone living with HIV/AIDS.16 17 18 Implementing TasP requires ART commencing 
immediately upon the detection of infection, not waiting for immune suppression. This 
greatly expands the number of people needing ART and a mechanism to pay for it. All of 
this assumes early detection through regular HIV testing.  
The following research explored barriers to HIV testing within the MSM 
community. Research has suggested that the top barriers for testing in the MSM 
community are fear of a positive test result and low perceived risk for HIV infection.19 20 
21 This study reports on findings from a survey that was distributed among MSM in 
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Buffalo and Rochester, New York. This research focused specifically on reasons for not 
taking an HIV test among MSM. For TasP to be effective, widespread testing in order to 
identify HIV-positive people is needed.22 There are significant barriers to TasP, including 
the barriers to getting an HIV test. This study furthered assessed the barriers that exist 
and proposed ways to combat them. We hypothesized similar results to the 2006 study by 
Mikolajczak, in which a majority of MSM recorded that a fear of a positive test result and 
low perceived risk for HIV infection were their top reasons for not taking an HIV test.19  
Methods 
Subjects 
Surveys were conducted during June and July 2012 in gay pride venues in 
Rochester and Buffalo, NY. The survey included a brief consent statement in the 
directions. Participants were eligible if they self-reported being 18 years of age or older. 
This study examined responses from MSM, but all people were welcomed to participate. 
The College at Brockport Institutional Review Board granted ethical approval for this 
study. For ethical considerations, data recorded on the survey remained anonymous. 
Of the completed surveys, 84 identified as male and were included in the analysis; 
50 (59.5%) were from Buffalo, while 34 (40.5%) were from Rochester. Researchers 
conducted an independent samples T test using baseline data from Buffalo and Rochester. 
There were no significant differences in the means of descriptive variables between the 
two cities, thus allowing us to merge the two samples into one. Participants were of 
mixed ethnicities, but predominantly white (79.8%). Most (89.3%) of respondents 
identified as homosexual, while 10.7% identified as bisexual. There were five 
respondents who were HIV-positive, which yielded a prevalence of 6.8%. All participants 
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reported an age between 18 and 72, with the mean age of the population being 36 (SD = 
13.9) and a median age of 32.5. Respondents were generally well educated with a mean 
of 15.7 (SD = 3.1) years of education completed. The income reported showed a mean 
salary of approximately $45,000 (SD = $32,405). 
Instruments 
The survey included questions regarding demographics, sexual behavior, 
substance use behavior, testing behavior, knowledge about HIV risk, and barriers to HIV 
testing. The specific items of interests included barriers to HIV testing and testing 
behavior. 
Barriers to HIV testing. Respondents were asked to rate the importance of 15 
reasons for not taking an HIV test. Barriers to HIV testing and HIV risk were evaluated 
using a four-point Likert scale (1-strongly agree, 2-mildly agree, 3-mildy disagree, 4-
strongly disagree). Portions of the survey were adapted from an instrument developed by 
Mikolajczak.19 
HIV testing behavior. Research suggests that in order for TasP to work 
effectively, routine testing must occur. In order to assess compliance with the 
recommendation to take an HIV test annually, the instrument included the prompt 
“Months since last HIV test” with a space for a numeric response. Subjects who wrote in 
a number and indicated the response was in years (e.g., “10 years”) were coded with the 
appropriate number of months (e.g., 120 months). 
Based on previous research, the researches hypothesized a positive correlation 
between perceived risk of HIV infection and HIV testing behavior. Also, researchers 
hypothesized that there will be a negative correlation between fear of a positive test result 
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and HIV testing behavior. Spearman’s rank-order correlation coefficients were used to 
evaluate the relationship between each of the 15 HIV testing barrier items and months 
since last HIV test.  
Procedure 
For the purpose of the present study, a survey was created and distributed at pride 
venues in Rochester and Buffalo, NY. A small pencil was taped to each survey. Research 
staff administered the survey in person through tabling and canvassing the venue. To 
encourage the completion of the survey, a bottle of water was offered as an incentive. For 
convenience purposes, all surveys included a pre-paid postage; this would allow 
participants to complete the survey and return it after the event. There was no identifying 
information on the survey.  
In Buffalo, 920 surveys were distributed and 150 were completed, yielding a 
response rate of 16.3%. In Rochester, 222 surveys were distributed and 67 were 
completed, yielding a response rate of 30.2%. Overall, 1142 surveys were distributed and 
217 were completed, yielding a response rate of 19.0%. Male, female, and transgender 
respondents were among the 217 surveys completed. However, only the 84 male-
identified surveys were utilized for the current study. Surveys were stored in a locked file 
and remained confidential. Once the study concluded and surveys were received, the data 
was entered and analyzed using SPSS. 
Results 
In order for TasP to work successfully, there must be regular HIV testing to 
identify and treat HIV-positive people, thus decreasing viral load and transmissibility. 
This will only be accomplished through routine HIV testing, which should be performed 
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once every 12-months.13 It was hypothesized that the dependent variable of HIV testing 
would be related to barriers to testing. Months since last HIV test ranged from 0 to 348 
months (Mean = 24.59, SD = 62.01, Median = 5.0), resulting in a positively skewed 
dataset. 
The CDC recommends that sexually active MSM undergo routine testing at least 
once every 12 months. Among the participants, 5 (6.8%) identified as HIV-positive. 
Since they are unlikely to continue routine testing, these participants were excluded from 
further analysis. The study was continued with 79 participants who either identified as 
HIV negative or did not respond. Of those, 31 (39.2%) did not comply with the 
recommendation to get tested within the past 12 months. Forty-eight participants (60.8%) 
did comply with the recommendation and were tested within the past 12 months. 
There were 65 participants who answered the question regarding months since 
last HIV test. Responses were analyzed by correlating the 15 questions regarding barriers 
to HIV testing with months since last HIV test using a Spearman’s correlation. Three 
items were significantly correlated with months since last HIV test (see Table 1). The 
positive correlation of lack of perceived support with months since last HIV test (r = 
.210, p = .047) suggested that participants who receive more support are more likely to 
have not been tested recently. The positive correlation between being partnered and 
months since last HIV test (r = .343, p = .003) suggested that participants in relationships 
were more likely to have not been tested recently. The positive correlation between not 
knowing where to get tested and months since last HIV test (r = .216, p = .042) suggested 
that participants who were knowledgeable about testing sites were more likely to have 
not been tested recently. 
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In summary, three barriers were significantly correlated with HIV testing. These 
were relationship status, perceived support, and knowledge of test sites. However, two of 
these relationships, perceived support and knowledge of test sites, were opposite of the 
expected direction. The barriers identified by previous research, fear of a positive test 
result and low perceived risk were not significantly correlated with months since last HIV 
test. 
Discussion 
 In order to reduce incidence and prevalence of HIV, TasP has been identified as 
an important public health strategy. Reduced transmissibility would be achieved via 
reduced viral load subsequent to ART. However, successful ART requires identification 
of new HIV infections through regular HIV testing. Therefore, barriers to HIV testing 
were the focus this study.  
This study discovered that roughly 40% of participants had not been tested within 
the last year. TasP would not be an effective technique to prevent transmission among an 
untested group such as this. Previous research suggested that fear of a positive result and 
low perceived risk were barriers to testing. Interestingly, these findings were not 
replicated in this sample. However, previous research reported the means of variables but 
did not correlate them with testing behaviors.19 Among respondents, three reasons for not 
taking an HIV test were found to be significantly correlated with months since last HIV 
test.  
The findings from this study showed that partnered men were less recently tested. 
TasP would not prevent HIV transmission among non-monogamous or recently single 
men who were not regularly tested. Also, this study suggested that participants who 
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receive more support were less recently tested. In addition, participants who were 
knowledgeable about testing sites were less recently tested. These two correlations were 
in the reverse direction than were hypothesized. The meaning of these findings is unclear 
and merits further quantitative or qualitative exploration. For TasP to be effective, 
interventions must be designed to encourage more frequent HIV testing and safer sex 
among partnered men and those who have not been recently tested. 
There are several limitations of this study that should be carefully considered. The 
number of participants was small and may not be representative of the overall MSM 
population. The current sample was not ethnically diverse, which was likely because of 
the traditional recruiting technique of advertising in highly attended MSM venues. In 
addition, recruiting participants solely in Rochester and Buffalo created a selection bias 
based on geography. As such, the barriers reported cannot be statistically generalized to a 
different sample and should only be compared with similar samples that are 
predominately white, college-educated, and of a similar socio-economic status.  
Self-reported behaviors can only be assessed in the context of a willingness to 
report. Participants may be less open and honest when answering questions on sensitive 
topics, especially in the presence of others. Further, correlation can only imply a 
relationship and cannot suggest cause and effect. This suggests the limitation that there 
may also be a third variable that caused the increase in months since last HIV test. A third 
variable may be related to the unexpected direction of the perceived support and 
knowledge of testing site barriers. For example, perhaps high levels of acculturation in 
the MSM/gay and HIV-aware community led to perceived support, knowledge of testing 
sites, a lowered perceived risk of HIV, and subsequently decreased testing compliance. 
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Additional research, perhaps qualitative or mixed-methods designs could shed light on 
these findings. 
There is a substantial proportion of MSM who are not participating in routine 
HIV testing. Existing prevention strategies might be somewhat effective, but further 
research should be completed to identify barriers to HIV testing. An increase in HIV 
testing rates might be evidenced with the availability of new diagnostic methods such as 
in-home oral HIV testing. Healthcare providers should discuss the benefits of early 
diagnosis and routine HIV testing with patients. Additional MSM-targeted prevention 
interventions and improved access to HIV testing will be needed to further reduce the risk 
of HIV infection. 
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Table I. Correlation Coefficients of 15 Reasons for Not Taking an HIV-Test and  
Months Since Last HIV Test 
	  
 
Note. Items adapted from Mikolajczak (2006)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I have never taken an HIV test because…  Correlation 
Coefficient 
Sig. 
1(tailed) 
1. I think I have never been at risk for infection  
2. A positive result would turn my life upside down  
3. I have never had unprotected sex  
4. I am afraid of the consequences of a positive test result  
5. I don’t like talking about my sex life with a doctor or nurse  
6. I would rather not know whether I am infected  
7. I would rather not have counseling before and after the test  
8. I don’t expect a lot of support and understanding of my friends if 
I would do it 
9. I don’t expect a lot of support and understanding of my friends 
when I turn out HIV-positive 
10. I would rather not talk about it with my partner 
11. I am sure that the current medicines still have too many side 
effects 
12. I have not yet met the “right guy”  
13. I do not know where I can get tested  
14. There are no good medicines and you can’t do anything about it 
15. Because I am afraid of blood and needles 
-.012 
-.043 
.115 
-.024 
.067 
.041 
-.004 
 
.210 
 
.081 
.035 
 
.064 
.343 
.216 
.106 
.020 
.461 
.365 
.180 
.425 
.299 
.372 
.489 
 
.047 
 
.263 
.392 
 
.309 
.003 
.042 
.201 
.437 
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